Xinmai Medical Announces Strategic Collaboration with Israel’s Rainbow Medical and Files IPO Prospectus

Recently, SyMap announced a strategic cooperation agreement with Rainbow Medical, a renowned Israeli medical device incubator, and its incubated company Pythagoras Medical. SyMap will fully own the global rights to all assets of Pythagoras Medical, including the CE-certified renal nerve mapping system, all patents, trademarks, and know-how. Both parties will engage in deep collaboration in the field of renal artery ablation/renal denervation (RDN) to introduce more disruptive innovative medical devices addressing unmet clinical needs. This strategic cooperation will further enhance and solidify SyMap's patent portfolio, ensuring and reinforcing its leading position in the RDN field.

Rainbow Medical was founded in 2007, dedicated to disruptive medical innovations and inventions while focusing on solving significant health challenges and addressing the most urgent market needs. Its founder, Mr. Yossi Gross, personally holds over 700 patents. Products from several companies incubated by Rainbow Medical have obtained CE certificates and U.S. FDA approval, generating billions of dollars in revenue.

SyMap is an innovative medical device enterprise based in China with a global perspective and operational capabilities. It was co-founded by Professor Wang Jie, a top expert in the global cardiovascular field, former Dean of Nanjing University Medical School, former Executive Vice Dean of Jiangsu Provincial Academy of Clinical Medicine, Cardiology Department of Columbia University Medical School, and Renowned Jiangsu Province People’s Hospital, along with seasoned healthcare industry expert Jin Kewen. SyMap focuses on developing disruptive therapies/innovative devices for major diseases in the cardiovascular/respiratory fields and possesses a truly First-In-Class product pipeline. SyMap has a comprehensive product pipeline and is currently conducting two clinical registration trials: the SMART Study, which features the world's only renal nerve mapping/selective ablation system for treating hypertension, and the BATA Study, which uses a proprietary bronchial radiofrequency ablation system to treat severe asthma. Both products have entered the National Medical Products Administration’s special review process for innovative medical devices ("Green Channel").

Pythagoras Medical, incubated by the renowned Israeli incubator Rainbow Medical in 2014, is committed to the innovative development of precise renal nerve mapping and ablation products for the treatment of hypertension. The company's ConfidenHT™ product has undergone clinical human validation studies in Europe and obtained CE certification.

ConfidenHT™ System Product